Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

被引:0
|
作者
Ahmad, Zahoor [1 ]
Tyagi, Sandeep [1 ]
Minkowski, Austin [1 ]
Almeida, Deepak [1 ]
Nuermberger, Eric L. [1 ]
Peck, Kaitlin M. [2 ]
Welch, John T. [2 ]
Baughn, Anthony S. [3 ]
Jacobs, Williams R., Jr. [3 ]
Grosset, Jacques H. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] SUNY Albany, Dept Chem, Albany, NY 12222 USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10467 USA
基金
美国国家卫生研究院;
关键词
Experimental chemotherapy; mouse; pyrazinamide; tuberculosis; VITRO ANTIMYCOBACTERIAL ACTIVITY; PYRAZINOIC ACID-ESTERS; ANTITUBERCULOSIS ACTIVITY; DRUG PYRAZINAMIDE; TUBERCLE BACILLI; MURINE MODEL; MUTATIONS; PNCA;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens. This drug has a unique sterilizing activity against Mycobacterium tuberculosis. Its unique role in tuberculosis treatment has lead to the search and development of its structural analogues. One such analogue is 5-chloro-pyrazinamide (5-Cl-PZA) that has been tested under in vitro conditions against M.-tuberculosis. The present study was designed with an aim to assess the activity of 5-Cl-PZA, alone and in combination with first-line drugs, against murine tuberculosis. Methods: The minimum inhibitory concentration (MIC) of 5-Cl-PZA in Middlebrook 7119 broth (neutral pH) and the inhibitory titre of serum from mice that received a 300 mg/kg oral dose of 5-Cl-PZA 30 min before cardiac puncture were determined. To test the tolerability of orally administered 5-Cl-PZA, uninfected mice received doses up to 300 mg/kg for 2 wk. Four weeks after low-dose aerosol infection either with M. tuberculosis or M. bovis, mice were treated 5 days/wk with 5-Cl-PZA, at doses ranging from 37.5 to 150 mg/kg, either alone or in combination with isoniazid and rifampicin. Antimicrobial activity was assessed by colony-forming unit counts in lungs after 4 and 8 wk of treatment. Results: The MIC of 5-Cl-PZA against M. tuberculosis was between 12.5 and 25 mu g/ml and the serum inhibitory titre was 1:4. Under the same experimental conditions, the MIC of pyrazinamide was >100 mu g/ml and mouse serum had no inhibitory activity after a 300 mg/kg dose; 5-Cl-PZA was well tolerated in uninfected and infected mice up to 300 and 150 mg/kg, respectively. While PZA alone and in combination exhibited its usual antimicrobial activity in mice infected with M. tuberculosis and no activity in mice infected with M. bovis, 5-Cl-PZA exhibited antimicrobial activity neither in mice infected with M tuberculosis nor in mice infected with IV. bovis. Interpretation & conclusion: Our findings showed that 5-Cl-PZA at doses up to 150 mg/kg was not active in chronic murine TB model. Further studies need to be done to understand the mechanism and mode of inactivation in murine model of tuberculosis.
引用
收藏
页码:808 / 814
页数:7
相关论文
共 50 条
  • [21] A promoter mutation causes differential nitrate reductase activity of Mycobacterium tuberculosis and Mycobacterium bovis
    Stermann, M
    Sedlacek, L
    Maass, S
    Bange, FC
    JOURNAL OF BACTERIOLOGY, 2004, 186 (09) : 2856 - 2861
  • [22] TUBERCULIN HYPERSENSITIVITY HEPATITIS IN MICE INFECTED WITH MYCOBACTERIUM BOVIS (BCG)
    FERLUGA, J
    AMERICAN JOURNAL OF PATHOLOGY, 1981, 105 (01): : 82 - 90
  • [23] ANALYSIS OF THE CELLULAR IMMUNE-RESPONSE OF MYCOBACTERIUM-BOVIS-INFECTED AND MYCOBACTERIUM-LEPRAE-INFECTED MICE
    MULLER, I
    KAUFMANN, SHE
    ZENTRALBLATT FUR BAKTERIOLOGIE MIKROBIOLOGIE UND HYGIENE SERIES A-MEDICAL MICROBIOLOGY INFECTIOUS DISEASES VIROLOGY PARASITOLOGY, 1986, 262 (02): : 258 - 258
  • [24] Influence of Advanced Age on Mycobacterium bovis BCG Vaccination in Guinea Pigs Aerogenically Infected with Mycobacterium tuberculosis
    Komine-Aizawa, Shihoko
    Yamazaki, Toshio
    Yamazaki, Tsuyoshi
    Hattori, Shin-ichiro
    Miyamoto, Yuji
    Yamamoto, Naoki
    Haga, Shinji
    Sugitani, Masahiko
    Honda, Mitsuo
    Hayakawa, Satoshi
    Yamamoto, Saburo
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (10) : 1500 - 1506
  • [25] Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides
    Rai, Dinesh
    Johar, Monika
    Srivastav, Naveen C.
    Manning, Tracey
    Agrawal, B.
    Kunimoto, Dennis Y.
    Kumar, Rakesh
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (19) : 4766 - 4774
  • [26] Immune Responses in Cattle Inoculated with Mycobacterium bovis, Mycobacterium tuberculosis, or Mycobacterium kansasii
    Waters, W. R.
    Whelan, A. O.
    Lyashchenko, K. P.
    Greenwald, R.
    Palmer, M. V.
    Harris, B. N.
    Hewinson, R. G.
    Vordermeier, H. M.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (02) : 247 - 252
  • [27] Enzymatic inactivation and reactivation of chloramphenicol by Mycobacterium tuberculosis and Mycobacterium bovis
    Sohaskey, CD
    FEMS MICROBIOLOGY LETTERS, 2004, 240 (02) : 187 - 192
  • [28] Concurrent Mycobacterium tuberculosis and Mycobacterium bovis infections in a patient with AIDS
    LoBue, PA
    Peter, C
    Tracy, M
    Moser, K
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2001, 5 (12) : 1164 - 1165
  • [29] Mycobacterium bovis and Other Uncommon Members of the Mycobacterium tuberculosis Complex
    Esteban, Jaime
    Munoz-Egea, Maria-Carmen
    MICROBIOLOGY SPECTRUM, 2016, 4 (06):
  • [30] A pncA polymorphism to differentiate between Mycobacterium bovis and Mycobacterium tuberculosis
    Barouni, AS
    Augusto, CJ
    Lopes, MTP
    Zanini, MS
    Salas, CE
    MOLECULAR AND CELLULAR PROBES, 2004, 18 (03) : 167 - 170